Clinical Trials Logo

Effects of Chemotherapy clinical trials

View clinical trials related to Effects of Chemotherapy.

Filter by:

NCT ID: NCT05529940 Not yet recruiting - Clinical trials for Neoadjuvant Chemotherapy

NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)

Start date: September 2023
Phase: Phase 3
Study type: Interventional

Rationale: Adjuvant chemotherapy after surgery significantly improved the survival of PC patients, but there is a problem that only about 50% of patients start adjuvant chemotherapy after pancreatectomy. Neoadjuvant chemotherapy might control potential metastatic lesion which are not being detected in early diseases status and improve the R0 resection rate. In addition, it prevents futile surgery by selecting patients with rapid progression of disease. Furthermore, compared to chemotherapy administered after surgery, more patients can complete the planned chemotherapy schedule in neoadjuvant setting. Asians differ from Westerners not only in racial differences, but also in average size and body surface area. Accordingly, there is an urgent need for clinical studies on the dose, toxicity, dosing cycle, and efficacy of anticancer drugs that reflect actual clinical trials in Asian countries for Asians. There are still few studies worldwide that prospectively explored the efficacy of neoadjuvant chemotherapy in resectable PC and the administration of neoadjuvant therapy in resectable PC depends on individual clinical judgment. Therefore, systematic and prospective clinical trials are essential to standardize treatment protocol in resectable PC. Obective: To investigate whether 6 cycles of preoperative mFOLFIRINOX - surgery - 6 cycles of postoperative mFOLFIRINOX improves overall survival by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX. Study design: open-label, multicenter, randomized, phase 3 clinical trial Study population: Patients with resectable pancreatic cancer and ECOG performance 0 or 1. Intervention: Invervention arm : 6 cycles of neoadjuvant mFOLFIRINOX followed by surgical resection and 6 cycles of adjuvant mFOLFIRINOX Comparator arm : surgical resection followed by 12 cycles of adjuvant mFOLFIRINOX Primary endpoint: 2-year overall survival rate by intention-to-treat

NCT ID: NCT05338073 Recruiting - Cancer Clinical Trials

KM3D Multicenter Cancer Consortium: Predicting Patient Response Using 3D Cell Culture Models

Start date: January 12, 2021
Phase:
Study type: Observational

This study will assess the ability of the Known Medicine platform to predict the efficacy of certain cancer drug treatments and to validate that tumor organoid drug sensitivity is representative of patient treatment outcomes.

NCT ID: NCT05268991 Recruiting - Aging Clinical Trials

Aging and Frailty Study

Start date: May 2, 2022
Phase:
Study type: Observational

The purpose of this research study is to compare methods to help personalize the prediction of chemotherapy side effects for older adults and to evaluate whether chemotherapy causes changes in the body that are associated with aging.

NCT ID: NCT04999332 Recruiting - Gastric Cancer Clinical Trials

Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer

LOTS
Start date: December 10, 2021
Phase: Phase 2
Study type: Interventional

The aim of the trial is to investigate the clinical efficacy and toxicity of perioperative chemotherapy with leucovorin, oxaliplatin, docetaxel and S-1 (LOTS) in patients with locally advanced gastric or gastroesophageal junction adenocarcinoma who receive a curative surgery.

NCT ID: NCT04544969 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC

Start date: April 1, 2020
Phase:
Study type: Observational [Patient Registry]

The prospective observational clinical study will recruit 50 metastatic nasopharyngeal carcinoma (mNPC) patients, detecting patient's chemosensitivity with the circulating tumor cells (CTCs) from peripheral blood and prdicting patient's treatment efficacy with CTCs dynamic change.

NCT ID: NCT03885388 Recruiting - Drug Toxicity Clinical Trials

Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma (GTN) Patients With Score of 5-6

Start date: March 8, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

In this study, a prospective, multicenter randomized controlled study was conducted to compare the clinical efficacy and toxicity response of combination MTX+ACTD multi-course regimen in low-risk GTN patients with score 5-6 with standard MTX single-drug multi-course regimen.

NCT ID: NCT03840824 Completed - Clinical trials for Premature Ovarian Failure

Blood Spot Self-administered Test and Assay

Start date: October 2010
Phase:
Study type: Observational

The current study will compare hormone levels of AMH, FSH and inhibin B in blood specimens collected by venipuncture and fingerstick in a sample of pre-menopausal women ages 18-45 years with normal menstrual cycles.

NCT ID: NCT03402295 Completed - Multiple Myeloma Clinical Trials

Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation

GBRAM003r
Start date: June 15, 2009
Phase: Phase 3
Study type: Interventional

This study compared two main different induction protocols used to treat myeloma eligible patients in Brazil. VCD against CTD.

NCT ID: NCT03197532 Completed - Clinical trials for Effects of Chemotherapy

Assessing Urinary Hormones in Female Cancer Survivors

AUHS
Start date: January 2011
Phase:
Study type: Observational

Women of late to mid reproductive age may participate in a study using novel methodology to identify subtle changes in the reproductive endocrine axis via daily urine hormone analysis, which may have important implications for reproduction and may signal reproductive senescence.

NCT ID: NCT03006614 Recruiting - Breast Cancer Clinical Trials

PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer

PERS
Start date: April 2016
Phase: Phase 3
Study type: Interventional

This study aims to explore new PERS prediction model can improve the pathological complete response rate of neoadjuvant chemotherapy of breast cancer and disease-free survival.